secwatch.observer — SEC 8-K summary
======================================

Issuer:     RIGEL PHARMACEUTICALS INC (RIGL)
CIK:        0001034842
Form:       8-K
Filed at:   2024-01-08T23:59:59+00:00
Accession:  0001104659-24-002085
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rigel prelim Q4 2023 total revenue ~$35.7M; TAVALISSE record $25.7M; MD Anderson deal $15M
--------------------------------------------------------------------------------

- Prelim Q4 total revenue ~$35.7M: TAVALISSE net sales $25.7M (record), REZLIDHIA $3.9M.
- Full-year 2023 net product sales $104.3M (+36% YoY); cash & investments $56.9M at year-end.
- Strategic collaboration with MD Anderson to advance REZLIDHIA in AML and other cancers; $15M in milestones over 5 years.
- Collaboration with CONNECT for Phase 2 trial of REZLIDHIA in IDH1-mutant glioma; Rigel funding up to $3M.
- Phase 1b trial of R289 (IRAK1/4 inhibitor) in lower-risk MDS currently enrolling third cohort.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1034842/000110465924002085/0001104659-24-002085-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1034842/000110465924002085/tm242328d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-002085

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer